PRLog (Press Release) -
Aug 17, 2010 -
MusclePharm Corporation (OTCBB:MSLP.OB)
, one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, announced today that MusclePharm athlete and NFL star Joey Porter will wear MusclePharm’
s new clothing line during a 17-episode weekly series spanning the 2010 NFL season on NFL Network.
The new MusclePharm-
branded hats and shirts will be unveiled to the retail market in the coming weeks and Porter’s notoriety in the world’s most popular sport presents an ideal platform to create exposure for the product line.
MusclePharm’
s top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside. Headquartered in Aurora, Colorado, the company is a fast-growing developer and manufacturer of safe, scientifically approved, nutritional supplements that are free of banned substances and tested by athletes. They are designed to help athletes, bodybuilders, weightlifters and fitness enthusiasts improve their performance. Each and every MusclePharm product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists.
Biostar Pharmaceuticals, Inc. (Nasdaq:BSPM)
, a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results of the second quarter ended June 30, 2010. Second quarter revenue increased 46.4% to $19.4 million.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar currently manufactures two broad-based OTC products, two prescription-
based pharmaceuticals, one medical device and five health supplements.
Johnson & Johnson (NYSE:JNJ) 1DAY ACUVUE TRUEYE Brand Contact Lenses recently became the fifth contact lens in the ACUVUE family of products to receive the Seal of Acceptance for Ultraviolet Absorbing Contact Lenses from the American Optometric Association's Commission on Ophthalmic Standards.
ACUVUE Brand Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from VISTAKON, Division of Johnson & Johnson Vision Care, Inc.
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
Sign Up for our Free Stock Newsletter at http://www.pennyotcstock.com/
signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOtcStock.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyotcstock.com/
disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).
